Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
|Articles|November 1, 2012
Timing of hormone therapy and Alzheimer's disease
Women who begin hormone therapy (HT) within 5 years of menopause have a lower risk of Alzheimer's disease (AD) than those who do not use HT, so say the findings of a population-based study.
Advertisement
Advertisement
Related to this article
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Jessica Shepherd, MD, MBA, FACOG, joins Missed & Dismissed to discuss why perimenopause is overlooked and how disparities shape who gets care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
3
Matthew Nudy, MD, on estrogen and the cardiovascular system
4
Susan Reed, MD, on the future of menopause research and funding
5